Skip to content
OpenCapital
Get started

Atea Pharmaceuticals, Inc. AVIR Q4 2024 Annual earnings

Reported March 6, 2025 · After market close

Diluted EPS-$0.40Miss by $0.05
EPS estimate-$0.35

Next report

Aug 6, 2026 (In 3 weeks)
Revenue estimate$33.0M
EPS estimate-$0.56

Versus estimates

Diluted EPS

Q1 2026-$0.57Beat by $0.03Q4 2025-$0.57Miss by $0.08Q3 2025-$0.53Miss by $0.07Q2 2025-$0.44Beat by $0.02Q1 2025-$0.40Beat by $0.16
Q4 2024-$0.40Miss by $0.05

Ask the moment Atea Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Atea Pharmaceuticals, Inc. report Q4 2024 earnings?
Atea Pharmaceuticals, Inc. (AVIR) reported Q4 2024 earnings on March 6, 2025 after market close.
What were Atea Pharmaceuticals, Inc.'s Q4 2024 revenue and EPS?
Atea Pharmaceuticals, Inc. reported diluted EPS of $-0.40 for Q4 2024.
Did Atea Pharmaceuticals, Inc. beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.35 by $0.05.
Where can I find Atea Pharmaceuticals, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-034808) directly on SEC EDGAR. The filing index links above go to sec.gov.